STOCK TITAN
  1. Home
  2. Sec-filings
  3. FDMT
  4. [Form 4] 4D Molecular Therapeutics, Inc. Insider Trading Activity

4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. executive Scott Bizily, Chief Legal Officer, reported paired option exercises and stock sales in FDMT. On August 13, 2026 and August 17, 2026, Bizily exercised stock options covering 1,635 shares of common stock on each date at an exercise price of $4.14 per share, converting a total of 3,270 stock option rights into common shares. On each of those dates, he then sold 1,635 shares of common stock in open-market or private transactions at per-share prices of $12.00 and $12.20, respectively. These sales were made pursuant to a Rule 10b5-1 trading plan adopted on January 13, 2026. The exercised options relate to an award that vests monthly, with 1/48th of the underlying shares vesting each month starting on March 6, 2025 until fully vested on the fourth anniversary, while Bizily remains a service provider.

Positive

  • None.

Negative

  • None.
Insider Bizily Scott
Role Chief Legal Officer
Sold 3,270 shs ($40K)
Approx. gross sale proceeds $40K
Approx. exercise cost $14K
Approx. pre-tax spread $26K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F2 1,635 $0.00 $0.00
Exercise Common Stock 1,635 $4.14 $7K
Sale Common Stock F1 1,635 $12.20 $20K
Exercise Stock Option (Right to Buy) F2 1,635 $0.00 $0.00
Exercise Common Stock 1,635 $4.14 $7K
Sale Common Stock F1 1,635 $12.00 $20K
Holdings After Transaction: Stock Option (Right to Buy) — 59,701 shares (Direct); Common Stock — 8,617 shares (Direct)
Footnotes (2)
  1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.
  2. F2. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Shares sold 2026-08-13 1635 shares Common Stock sale on August 13, 2026 at $12.0000 per share
Shares sold 2026-08-17 1635 shares Common Stock sale on August 17, 2026 at $12.2000 per share
Options exercised total shares 3270 shares Stock option exercises (2 transactions) at $4.1400 exercise price per share
Option exercise price $4.1400 per share Conversion or exercise price for Stock Option (Right to Buy) into Common Stock
Option expiration date 2035-03-05 Expiration date for the Stock Option (Right to Buy) underlying the exercised shares
Vesting commencement date March 6, 2025 Monthly vesting of 1/48th of the option shares from this date
10b5-1 plan adoption date January 13, 2026 Adoption date of the Rule 10b5-1 trading plan governing the reported sales
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy financial
"security_title": "Stock Option (Right to Buy)"
Vesting Commencement Date financial
"on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date")"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
service provider other
"while the grantee remains a service provider to the Company"

FAQ

What did FDMT executive Scott Bizily report in this Form 4?
Scott Bizily reported option exercises and related stock sales in 4D Molecular Therapeutics (FDMT). He exercised options for 3,270 shares total at $4.14 per share and sold 3,270 shares in two transactions at $12.00 and $12.20 per share.

How many FDMT shares did Scott Bizily sell and at what prices?
Scott Bizily sold 3,270 shares of FDMT common stock in total. He sold 1,635 shares on August 13, 2026 at $12.00 per share and another 1,635 shares on August 17, 2026 at $12.20 per share.

What stock options did Scott Bizily exercise in FDMT according to this Form 4?
Bizily exercised stock options for 1,635 shares of FDMT common stock on August 13, 2026 and 1,635 shares on August 17, 2026, at an exercise price of $4.14 per share. The options are scheduled to expire on March 5, 2035.

Were Scott Bizily’s FDMT stock sales under a Rule 10b5-1 plan?
Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Scott Bizily on January 13, 2026. Such plans pre-arrange trades, reducing the informational value of trade timing for market signaling.

How do Scott Bizily’s FDMT stock options vest?
The stock option award vests in 1/48th increments of the underlying shares on each monthly anniversary of March 6, 2025. The filing states that 100% of the option shares will be fully vested on the fourth anniversary, if he remains a service provider.

What is the expiration date of Scott Bizily’s exercised FDMT stock options?
The exercised FDMT stock options are scheduled to expire on March 5, 2035. Before expiration, the options vest monthly starting on March 6, 2025, becoming fully vested on the fourth anniversary while Scott Bizily continues as a service provider to the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bizily Scott
(Last)(First)(Middle)
C/O 4D MOLECULAR THERAPEUTICS, INC.
5858 HORTON STREET #455
(Street)
EMERYVILLE CALIFORNIA 94608
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/13/2026M1,635A$4.1410,252D
Common Stock08/13/2026S(1)1,635D$128,617D
Common Stock08/17/2026M1,635A$4.1410,252D
Common Stock08/17/2026S(1)1,635D$12.28,617D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$4.1408/13/2026M1,635 (2)03/05/2035Common Stock1,635$061,336D
Stock Option (Right to Buy)$4.1408/17/2026M1,635 (2)03/05/2035Common Stock1,635$059,701D
Explanation of Responses:
1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.
2. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
/s/ Scott Bizily08/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR